BridgeBio (BBIO) Pharma provided updates on its commercial progress for Attruby, status of late-stage pipeline programs, and anticipated 2026 milestones. These updates were presented by co-founder and CEO, Neil Kumar, Ph.D., at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Monday, January 12 at 7:30 am PT. “BridgeBio was built on the belief that if you start with patients, move with urgency, and stay disciplined on science and data, you can deliver transformative medicines with unprecedented results quickly, safely, and effectively,” said Dr. Kumar. “Over the past decade, we’ve built a company that proves this model. Today, we’re seeing progress widely across that decentralized model, allowing us to drive impact for several different communities and hopefully doubling the number of patients that we’re able to serve by the end of 2026.”
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BBIO:
- BridgeBio price target raised to $86 from $80 at Truist
- BridgeBio initiated with an Overweight at Morgan Stanley
- BridgeBio Pharma: Emerging Rare Disease Leader With Robust Growth Outlook and Discounted Valuation Supporting Buy Rating
- Ionis Pharmaceuticals price target raised to $100 from $85 at Leerink
- Alnylam price target lowered to $351 from $370 at Leerink